Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

In Monday's intraday session, several healthcare stocks experienced significant movements. Etao International Co led the gainers with a 96.6% increase, while Universe Pharmaceuticals topped the losers, declining by 18.2%. Other notable movers included Longeveron, Adlai Nortye, and Onconetix on the gainers' side, and Agenus, MiNK Therapeutics, and CNS Pharma among the losers.

Portfolio Pulse from Benzinga Insights

April 08, 2024 | 4:31 pm

In Friday's pre-market session, health care stocks showed significant movement. Protara Therapeutics led the gainers with a 40.3% increase, while Aesthetic Medical Intl experienced the largest drop among the losers, declining by 17.8%. Other notable movers include Candel Therapeutics and Etao International with substantial gains, and TC BioPharm and Imunon among the losers.

Portfolio Pulse from Benzinga Insights

April 05, 2024 | 12:09 pm

Reliance Global Group, Inc. (RELI) shares fell by 11.3% in pre-market trading after reporting a net loss of $12.0 million for 2023, contrasting with a net income of $6.5 million in 2022. Other stocks showed significant movement in pre-market trading, with notable gainers including MediaCo Holding Inc. (MDIA), Nutex Health Inc. (NUTX), and 22nd Century Group, Inc. (XXII), among others. Losers included Semantix, Inc. (STIX) and HWH International Inc. (HWH), with STIX reporting a voluntary delisting from the Nasdaq Global Market.

Portfolio Pulse from Avi Kapoor

April 05, 2024 | 9:45 am

U.S. stocks declined with the Dow Jones falling over 200 points. RPM International's shares dropped after Q3 results, showing a slight sales increase but beating EPS estimates. TCBP, ALUR, and CADL shares surged on positive news, while EFTR, ACHL, and KWE shares plummeted due to disappointing updates. Oil and gold prices rose.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 6:39 pm

TC BioPharm's stock is trading higher following the announcement of a non-binding letter of intent, which is part of its M&A strategy to expand its therapeutic platform and leverage NK cells for treating solid tumors and other indications.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 4:34 pm

Health care stocks experienced significant movements in Thursday's intraday session. Candel Therapeutics, TC BioPharm, Eiger BioPharmaceuticals, Macrogenics, Barinthus Biotherapeutics, and Curis saw notable gains, with increases ranging from 24.62% to 64.3%. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, Inotiv, Universe Pharmaceuticals, Kintara Therapeutics, and Carmell faced declines, with decreases ranging from 12.85% to 80.2%. The movements were attributed to various factors, including earnings releases and market dynamics.

Portfolio Pulse from Benzinga Insights

April 04, 2024 | 4:31 pm

Nasdaq rose 1% with ConAgra Brands reporting better-than-expected Q3 earnings, leading to a positive market sentiment. Real estate and healthcare sectors saw gains, while TC Biopharm, Allurion Technologies, and Candel Therapeutics experienced significant stock increases. Conversely, eFFECTOR Therapeutics, Achilles Therapeutics, and KWESST Micro Systems saw notable declines. Oil prices slightly dropped, while gold and silver prices increased.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 3:58 pm

U.S. stocks traded higher with the Dow Jones gaining over 100 points. Real estate shares led gains, while U.S. jobless claims rose to 221,000. TCBP surged 118% after announcing a letter of intent for an acquisition. ALUR jumped 61% following the commercial availability of its Virtual Care Suite and a positive analyst rating. TVGN gained 55% after a new executive appointment. EFTR, KYCH, and KWE saw significant drops due to various company-specific news.

Portfolio Pulse from Avi Kapoor

April 04, 2024 | 2:02 pm

TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced the execution of a non-binding letter of intent for the acquisition of NK platform technologies, aiming to expand its therapeutic platform. The acquisition targets proprietary manufacturing processes of two allogeneic CAR-NK therapeutics, focusing on solid tumors. The company sees substantial synergies in combining these with its TCB-008 therapy. The completion of the transaction is subject to various conditions including financing and regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:34 pm

TT BioPharm has been granted a European patent (EP3283620) for 'Modified Gamma Delta Cells and Uses Thereof' aimed at treating cancer or infectious diseases in humans. This development could potentially enhance the company's intellectual property portfolio and strengthen its position in the biopharmaceutical sector, particularly in the European market.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 7:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.